| Not Yet Recruiting | Navigation Intervention for Adolescent and Young Adult Cancer Survivors NCT07406087 | Kaiser Permanente | N/A |
| Not Yet Recruiting | Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma NCT07501104 | Shanghai Zhongshan Hospital | Phase 2 |
| Not Yet Recruiting | Investigating Real-Time Immunotherapy Symptoms Study NCT07280715 | University of Pittsburgh | N/A |
| Not Yet Recruiting | Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis NCT07376512 | Centre Georges Francois Leclerc | — |
| Not Yet Recruiting | PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor NCT07442292 | Peking University Cancer Hospital & Institute | — |
| Recruiting | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676 | Essen Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | SL-28 for Advanced Solid Tumours NCT07341737 | Second Life Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors NCT07287917 | Aminex Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | CARE-Melanoma Trial NCT07320222 | McMaster University | Phase 1 |
| Recruiting | Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma NCT07349303 | Vastra Gotaland Region | Phase 2 |
| Not Yet Recruiting | Investigation of the ROle of faT and inflAmmaTory Cells in mElanoma NCT07293598 | The Christie NHS Foundation Trust | — |
| Recruiting | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma NCT07288203 | Iovance Biotherapeutics, Inc. | Phase 2 |
| Not Yet Recruiting | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis NCT07246759 | OncoHost Ltd. | — |
| Recruiting | NO Re-excision MelanomA - NORMA 2 NCT07530887 | Marieke Goodijk | Phase 3 |
| Recruiting | IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma NCT07138222 | Peter MacCallum Cancer Centre, Australia | — |
| Not Yet Recruiting | Study of Melanoma-Resistant PET Monitoring Based on Key Rate-limiting Enzymes for Fatty Acid Metabolism in Hea NCT07114172 | Xijing Hospital | N/A |
| Recruiting | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma NCT06624644 | Linnaeus Therapeutics, Inc. | Phase 2 / Phase 3 |
| Recruiting | A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Me NCT07376707 | Hefei TG ImmunoPharma Co., Ltd. | Phase 1 |
| Recruiting | A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma. NCT07448831 | Universitair Ziekenhuis Brussel | Phase 2 |
| Recruiting | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies NCT07327489 | Elephas | — |
| Not Yet Recruiting | Investigation of the Performance of the Medical Device Dermalyser in Determining Melanoma Thickness Based on D NCT06788665 | Vastra Gotaland Region | — |
| Recruiting | Pan-tumor MRD Study NCT06605404 | Paradigm Health | — |
| Recruiting | Precision Medicine for L/GCMN and Melanoma 2 NCT06605443 | Fundacion Clinic per a la Recerca Biomédica | — |
| Recruiting | Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers NCT06608511 | University of Wisconsin, Madison | — |
| Recruiting | Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) NCT06545682 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions. NCT07428941 | AI Labs Group S.L | — |
| Completed | Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care NCT07428954 | AI Labs Group S.L | — |
| Recruiting | Precision Medicine for L/GCMN and Melanoma 1 NCT06608420 | Fundacion Clinic per a la Recerca Biomédica | — |
| Recruiting | A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Canc NCT07469709 | Fondazione del Piemonte per l'Oncologia | — |
| Recruiting | Reflectance Confocal Microscopy and Molecular Correlation in Atypical Melanocytic Lesions NCT07277920 | University of Modena and Reggio Emilia | — |
| Recruiting | Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young NCT06621810 | German Cancer Research Center | — |
| Completed | Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Co NCT07429123 | AI Labs Group S.L | — |
| Active Not Recruiting | ctDNA for Risk Stratification in Melanoma NCT07531121 | Herlev and Gentofte Hospital | — |
| Completed | Promoting Early Detection of Melanoma During the Mammography Experience NCT03057327 | Northwestern University | N/A |